Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C42H45N8+ and a molecular weight of approximately 661.9 g/mol[1][5]. It features a phenanthridinium core substituted with diamino and phenyl groups as well as an extended side chain containing both triazole and tetrahydroacridine moieties. The structure suggests potential DNA intercalating properties due to its planar aromatic system and cationic nature—features common among DNA-binding dyes or agents[7]. However, there is no evidence that this compound has been approved for clinical use or advanced beyond experimental investigation. Its mechanism of action is not explicitly described in available sources but may involve nucleic acid binding/intercalation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,8-diamino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]ethyl]-1h-1,2,3-triazol-5-yl]hexyl]-phenanthridinium.